Actively Recruiting
Evaluating Safety and Effectiveness of Beta-globin Restored Stem Cell Therapy for Children and Teens with Beta-Thalassemia Major
Led by Shenzhen Hemogen · Updated on 2024-11-29
10
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of b2-globin restored autologous hematopoietic stem cells in patients with b2-thalassemia major, a condition requiring regular blood transfusions. This early phase 1, open-label study focuses on restoring b2-globin expression to improve patient outcomes. The study is sponsored by Shenzhen Hemogen and targets children and adolescents aged 8 to 16 years with transfusion-dependent b2-thalassemia major. Participants will have their own hematopoietic stem cells collected and modified using the LentiHBBT87Q system to restore b2-globin production. After a conditioning process, these modified stem cells will be reinfused into the patients. Ten subjects aged 8 to 16 years will receive this treatment and be followed for two years to observe effects and safety. During the study, researchers will monitor adverse events, survival rates, engraftment success, viral replication, and viral integration over 24 months. Secondary measures include monitoring viral copy number in blood cells, adult hemoglobin expression, and changes in blood transfusion needs. Participants will undergo regular medical visits, treatments, and assessments throughout the two-year follow-up period to collect comprehensive data on treatment impact and safety.
CONDITIONS
Brief Title
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
Research Team
H
Haigang Sun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here